ProfileGDS5678 / 1448986_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 84% 83% 86% 86% 86% 86% 88% 87% 84% 84% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4024486
GSM967853U87-EV human glioblastoma xenograft - Control 26.2472684
GSM967854U87-EV human glioblastoma xenograft - Control 36.1986384
GSM967855U87-EV human glioblastoma xenograft - Control 46.2963283
GSM967856U87-EV human glioblastoma xenograft - Control 56.4987886
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3276586
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3207386
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4728486
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8177788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8039987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2070284
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3166884
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1860184
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1886784